The Randomised Embedded Multifactorial Adaptive Platform for Community Acquired Pneumonia (REMAP-CAP) is a clinical trial that simultaneously assesses the effectiveness of multiple treatments for critically ill people across 25 countries, including Singapore, to help intensive care units manage the expected surge in patients with breathing problems in future pandemics. With funding from National University of Singapore, the trial first commenced in Singapore at National University Hospital (NUH) n August 2022 and three patients have joined the study. The study will expand to Singapore General Hospital, Tan Tock Seng Hospital and Ng Teng Fong General Hospital this year with funding from National Medical Research Council.
Prof Paul Tambyah, Senior Consultant, Division of Infectious Diseases, NUH, and Dr Matthew Cove, Senior Consultant, Division of Respiratory & Critical Care Medicine, NUH, are senior investigators of the REMAP-CAP International Trial Steering Committee.